Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + Donafenib + Toripalimab for Unresectable HCC
NCT05493332Phase 2Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of donafenib and toripalimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Conversion therapy success rate at 2 years. Status: unknown.
02
Drugs
donafenibtoripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05493332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493332.